研報掘金丨東北證券:首予瑞普生物“增持”評級,發力寵物健康大產業
東北證券日前研報指出,瑞普生物(300119.SZ)爲動保行業領軍企業 ,發力寵物健康大產業。在下遊養殖業的週期性波動下,公司依然憑藉綜合競爭優勢和靈活的市場策略,實現了業績的平穩增長。同時,公司自2012年起前瞻性佈局寵物健康板塊,逐漸完善寵物藥苗產品體系的構建,並於2024 年初推出首個國產貓三聯疫苗,打破國外壟斷。此外,公司正在推進收購中瑞供應鏈和增持瑞派寵物醫院,通過整合上遊藥苗、中遊供應鏈、下遊客物醫院,構建完善的寵物大健康業務佈局。養殖業景氣回暖,動保需求有望得到提振。公司多款重磅產品陸續上市,大客戶合作不斷深化,市場份額望進一步提升。隨着寵物健康賽道佈局的推進,看好公司未來的發展前景。首次覆蓋,給與“增持”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.